Our business has needed to adapt during the COVID-19 outbreak, but we are still open and accepting new patients. Call or email us for more information.

Probiotics May Improve Metabolic Profiles

Most people generally associate probiotics with fostering the growth of good bacteria in the gut, however, more and more clinical studies are highlighting the role of probiotics beyond the gut. One randomized, placebo controlled, double-blind studylooked at the effects of probiotic supplementation on the metabolic profiles in diabetic patients with coronary heart disease (CHD).

Sixty diabetic patients with CHD, aged 40–85 years were evaluated at a cardiology clinic from October 2017 through January 2018. They were separated into two groups to take either probiotic supplements (n = 30) or placebo (n = 30) for 12 weeks, and randomly stratified based on age, BMI, gender, and medication use. The probiotic supplementation group received Bifdobacterium bifdum 2×109Lactobacillus casei2×109Lactobacillus acidophilus 2×109 CFU/day (n=30) or placebo (n=30) for 12 weeks.

In these diabetic patients with CHD, probiotic supplementation for 12 weeks had beneficial effects on glycemic control, HDL-cholesterol, total-/HDL-cholesterol ratio, and biomarkers of inflammation and oxidative stress. The researchers suggest these beneficial effects by the probiotics may be due to their ability to scavenge superoxide and hydroxyl radicals and decrease inflammatory signaling.

The group receiving probiotics had significantly decreased fasting plasma glucose (FPG) (β − 20.02 mg/dL; 95% CI − 33.86, − 6.17; P = 0.005), serum insulin levels (β − 2.09 μIU/mL; 95% CI − 3.77, − 0.41; P = 0.01), homeostasis model of assessment-insulin resistance (HOMA-IR) (β − 0.50; 95% CI − 0.96, − 0.03; P = 0.03) and total-/HDL-cholesterol ratio (β − 0.27; 95% CI − 0.52, − 0.03; P = 0.02), and significantly increased quantitative insulin sensitivity check index (QUICKI) (β 0.008; 95% CI 0.001, 0.01; P = 0.02), and HDL-cholesterol levels (β 2.52 mg/dL; 95% CI 0.04, 5.00; P = 0.04) compared with the placebo. In addition, hs-CRP levels were decreased, and both total antioxidant capacity and glutathione levels increased.

Thus, the researchers concluded that, “taking probiotics for 12 weeks by diabetic patients with CHD had beneficial effects on glycemic control, improving HDL levels- and total-/HDL-cholesterol ratio, and attenuating biomarkers of inflammation and oxidative stress.”

This research confirms previous findings where It has been reported that gut microbiota contribute to glucose homeostasis through different bacterial metabolites.iStock-1046974390

Comments are closed.

Main Navigation